Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Paul Bebbington and Elizabeth Kuipers, two academics whose lives are now impacted by Paul’s diagnosis of Alzheimer’s, offer brave accounts of the day-to-day experiences of living with dementia and being a care provider in an initiative to reduce stigma.
The annual event brings together basic scientists, clinical researchers, early career investigators, clinicians and the care research community to discuss the latest developments and innovation in Alzheimer’s and dementia research.
The Centers for Medicare & Medicaid Services (CMS) in the US confirms requirement for clinical trials to access Aduhelm but broadens which trials are eligible.
The study by Institute for Health Metrics and Evaluation (IHME) published in The Lancet predicts 153 million people will be living with Alzheimer’s disease by 2050.
This follows the result of the negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting in November.
As 2021 comes to an end, ADI CEO Paola Barbarino reflects on the work of ADI in 2021 and what we are looking towards to in 2022.
To date, only 37 of 194 countries that signed up to implement the WHO Global action plan on dementia have created and funded national dementia plans. Our new campaign aims to galvanise and encourage more governments to develop national dementia plans following their 2017 commitment.
The news follows a negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting.
Eisai’s lecanemab will represent the second anti-Amyloid Beta therapy to be evaluated by the FDA as a disease modifying treatment for early Alzheimer’s disease.
This report reviews progress towards the implementation of the 7 action areas of the plan by Member States, WHO and civil society, and all those involved in tackling the dementia pandemic.